购物车
- 全部删除
- 您的购物车当前为空
MYLS22 是视神经萎缩 1 的选择性抑制剂。它通过影响 NFkB 活性和血管生成基因表达抑制血管生成,靶向作用于内皮细胞 OPA1 ,减少肿瘤的生长。
为众多的药物研发团队赋能,
让新药发现更简单!
MYLS22 是视神经萎缩 1 的选择性抑制剂。它通过影响 NFkB 活性和血管生成基因表达抑制血管生成,靶向作用于内皮细胞 OPA1 ,减少肿瘤的生长。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 225 | 现货 | |
2 mg | ¥ 322 | 现货 | |
5 mg | ¥ 526 | 现货 | |
10 mg | ¥ 897 | 现货 | |
25 mg | ¥ 1,530 | 现货 | |
50 mg | ¥ 2,270 | 现货 | |
100 mg | ¥ 3,390 | 现货 | |
200 mg | ¥ 4,930 | 现货 | |
500 mg | ¥ 7,750 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 593 | 现货 |
产品描述 | MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity. |
体内活性 | MYLS22(10 mg/kg/天;肿瘤周围注射;每2天一次,连续14天)能够抑制小鼠的肿瘤生长。 |
分子量 | 443.52 |
分子式 | C24H21N5O2S |
CAS No. | 306959-01-3 |
Smiles | Cc1nn(-c2ccccc2)c2sc(cc12)C(=O)Nc1c(C)n(C)n(-c2ccccc2)c1=O |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 45 mg/mL (101.46 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
评论内容